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Abstract 
A kidney stone in a person with one kidney requires urgent attention which may result in 
surgical and/or hospital attention. We conducted a matched retrospective cohort study to 
determine if living kidney donors compared to healthy non-donors have a higher risk of: 1) 
kidney stones with surgical intervention, and 2) hospital encounters for kidney stones. We 
reviewed and linked information from pre-donation charts to Ontario healthcare databases. 
We selected healthy non-donors from the general population, matching ten non-donors to 
every donor, to generate a cohort of 2,019 donors and 20,190 non-donors. There was no 
difference in the rate of 1) kidney stones with surgical intervention comparing donors to non-
donors (8.3 vs 9.7 events/10,000 person-years; rate ratio[RR] 0.85; 95% confidence 
interval[CI] 0.47-1.53), and 2) hospital encounters for kidney stones (12.1 vs 16.1 
events/10,000 person-years; RR 0.75; 95% CI 0.45-1.24). These interim results are 
reassuring for the safety of living kidney donation. 
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Administrative data, kidney stones, calculi, living kidney donor, health outcomes, 
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Chapter 1: Introduction 
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1.1     Background & Overview  
Every year, over 27,000 individuals worldwide choose to undergo living kidney donation 
to help someone in need (1). Knowledge of the long-term outcomes of living kidney 
donors is required to maintain public trust in the transplantation system, inform the 
choices of potential donors and recipients, and to guide the follow-up care necessary to 
maintain optimal long-term health.  
One outcome that remains poorly understood in past living kidney donors is the 
subsequent development of kidney stones. In September 2012 we performed a detailed 
search of bibliographic databases (Pubmed, Google Scholar) and found only a few 
reports of living kidney donors being treated for kidney stones at the time of 
nephrectomy. However, these studies did not report the rate or long-term risk of kidney 
stones in this unique population. We expanded the search to include kidney stones in 
those with a solitary kidney for any reason and again found only literature discussing the 
management of the stone at the time of its occurrence. 
In the general population, kidney stones are common with an estimated lifetime risk of 
10-15% (2, 3). Most stones are small and pass through the urinary tract spontaneously 
within four weeks of initial symptoms. However, some stones may require surgical 
intervention including shockwave lithotripsy, ureteroscopy or percutaneous 
nephrolithotomy (3, 4). There is no reason to suspect that living kidney donors would 
have a higher risk of kidney stones than members of the general population. Yet, a kidney 
stone in an individual with a solitary kidney can potentially obstruct the ureter, leading to 
acute renal failure and may result in urgent hospital attention and even surgical 
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intervention (5).  This is also a concern because kidney stones can result in a decline in 
renal function, and this risk may be even higher in donors compared to non-donors. We 
conducted this matched retrospective cohort study to determine if living kidney donors 
compared to healthy non-donors have a higher risk of: 1) kidney stones with surgical 
intervention, and 2) hospital encounters for kidney stones. 
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Chapter 2: Literature Review 
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2.1 Kidney failure 
End-stage renal disease (ESRD) or kidney failure is the result of complications from 
reduced renal function, and is the most severe stage of chronic kidney disease (CKD) (6). 
The best measure of renal function used to assess the severity of kidney disease is called 
the glomerular filtration rate (GFR) (7). It represents an estimate of the amount of blood 
filtered by the glomeruli in the kidney per minute. The GFR of a healthy individual is 
typically around 90-120 mL/min per 1.73m
2
 (8). ESRD is characterized by either a 
reduction in estimated glomerular filtration rate (GFR) to level below 15 mL/min per 
1.73m
2
, or by the requirement of renal replacement therapy to prevent increased 
morbidity and mortality (6).  
The prevalence of end-stage renal disease or kidney failure is on the rise, with over one 
million individuals affected worldwide. This number continues to increase by 7% per 
year and in Canada alone the number of individuals living with end-stage renal disease 
has tripled over the past two decades (9, 10). Patients with ESRD require some form of 
renal replacement therapy in order to maintain life. 
2.2 Renal Replacement Therapy 
There are several different types of renal replacement therapy that can be used to treat 
patients with kidney failure. Dialysis involves the use of an artificial filtration system to 
clear the patient’s blood of toxic waste products. There are two main forms of dialysis. 
The first and most common form of dialysis is hemodialysis, which involves taking blood 
out of the patient’s body, filtering it through the dialysis machine and then pumping it 
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back into the patient (11). Typically a patient has to receive hemodialysis multiple times 
a week, with each treatment lasting 3-4 hours. The second form of dialysis is peritoneal 
dialysis, which allows the filtration to occur within the patient’s body through the 
introduction of fluid within the peritoneum. Waste products are filtered from the blood 
across the peritoneum membrane, and the fluid is then flushed out of the peritoneal cavity 
(11). Though the majority of patients with kidney failure are treated with dialysis, it is not 
their best treatment option. Dialysis is associated with numerous complications, reduced 
survival, and poorer quality of life when compared with transplantation (11-14).  
Compared to dialysis, transplantation is the preferred treatment option for end-stage renal 
disease resulting in 10 to 15 years longer survival (15). A systematic review of 110 
studies comparing kidney transplantation to dialysis concluded that transplantation was 
associated with significantly reduced mortality, reduced cardiovascular complications 
and improved quality of life (16). As well, the magnitude of the improvement in health 
with transplantation was found to increase over time (16).  
There are two types of transplantation – deceased donation or living donation. Deceased 
donation occurs after an individual dies as a result of brain death or cardiovascular 
collapse. In this case, the individual either registered or expressed their wish to become 
an organ donor prior to death (which is confirmed by family members of the deceased). 
Unfortunately the number of deceased donations has not been sufficient enough to meet 
the growing demand for organs. On the other hand, rates of living kidney donation are 
rising in an attempt to address this demand. Living kidney donation involves a living 
individual making the choice to donate one of their kidneys to someone in need.  
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2.3 Living kidney donation 
The first successful living kidney donation was performed by Dr. Murray in 1954 
between identical twins (17). Since then there have been significant advancements in 
transplant medicine and immunosuppression. Individuals who receive a kidney from a 
living donor have better outcomes with longer graft survival than those who receive a 
kidney from a deceased donor (18). The longer survival of a graft from a living kidney 
donor can be attributed to the fact that the kidney can be removed from the donor and 
transplanted into the recipient without delay. This minimizes the damage to the kidney 
due to ischemia, or loss of blood flow (19).   
A decision analysis of treatment options for patients with end-stage renal disease and 
type I diabetes demonstrated that transplants from living kidney donors were associated 
with 10.29 quality-adjusted life-years (QALY), while deceased donor transplants and 
dialysis treatments were associated with 6.53 QALY and 4.52 QALY respectively (20). 
Living kidney donation is also a more cost-effective treatment option for patients with 
end-stage renal disease. Dialysis is an expensive procedure, costing the healthcare system 
millions of dollars every year (21, 22). In Canada the cost for dialysis treatments is 
approximately $60,000 per patient per year, while in comparison the cost of a one-time 
kidney transplant is approximately $23,000 plus an additional $6000 for annual transplant 
medications (10). If all 3000 individuals on the wait list for a kidney transplant received a 
kidney, it would save the healthcare system an estimated $150 million dollars annually 
(23). 
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Rates of living kidney donation have been increasing worldwide to address the organ 
shortage, with over 27,000 individuals choosing to donate every year (1). Living donation 
is practiced under the framework that minimal medical risks faced by the donor are 
outweighed by better recipient health and possible psychological benefits of altruism to 
the donor (24). There is global consensus for a need to better understand the long-term 
risks faced by living kidney donors, a historically neglected area (25). For this reason, 
this topic has been the subject of active research. Better knowledge of the long-term 
outcomes of individuals who become living kidney donors maintains public trust in the 
transplantation system, informs the choices of potential donors and recipients, and guides 
follow-up care to maintain optimal long-term health. Recent high-quality studies have 
examined outcomes of mortality, cardiovascular events, end-stage renal disease, acute 
kidney injury with receipt of dialysis, and fragility fractures after kidney donation (26-
28). Reassuringly, these studies did not find an increase in risk, adding to the evidence 
base supporting the safety of the practice among carefully selected donors. However, 
there are still other important outcomes which remain to be studied. 
2.4 Kidney stones 
Kidney stones or renal calculi are a common occurrence, with a prevalence of 
approximately 5.2% in North America and an estimated lifetime risk of 10-15% (3, 29). 
After the development of a kidney stone, the risk of a subsequent stone increases with a 
recurrence rate of 75% over 20 years (2, 3). Kidney stones result from an abnormal 
urinary composition, which cause the crystallization of stone-forming salts. 
Approximately 80% of stones are formed from calcium-based salts, while the remainder 
form from compounds like uric acid, cystine and struvite (30). Abnormalities in urinary 
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composition can be caused by both metabolic and environmental factors (2). 
Environmental factors include hot climate (certain regions within the US are referred to 
as the ‘stone belt’ due to a higher prevalence of kidney stones because of climate), 
strenuous exercise, and diets rich in animal protein and salt. Metabolic factors include 
hypercalciuria (increased absorption of calcium in the intestine or decreased absorption in 
the kidney) and hypocitraturia (excess dietary acid) (2). 
Epidemiological studies have identified several risk factors associated with the formation 
of kidney stones. Literature describes males having a 2-3 times higher risk of developing 
kidney stones than females (29, 31, 32). The peak incidence of kidney stones occurs 
during the age range of 40-50 years (29, 33-35). 
2.5 Treating kidney stones  
The majority of stones are small enough to pass through the urinary tract spontaneously 
without any intervention. This typically occurs within four weeks after the onset of 
symptoms (4). However, if the kidney stone does not resolve with expectant 
management, a urologist may choose to surgically intervene using shockwave lithotripsy, 
ureteroscopy or percutaneous nephrolithotomy (4). Surgical procedures are usually 
required when stones are 3 mm or greater in size (3, 4). Approximately 10-20% of kidney 
stones are treated surgically (32). 
Extracorporeal shockwave lithotripsy is a procedure that involves targeting a shockwave 
from an external source, propagating through the patient’s body to the kidney stone 
causing it to break into smaller fragments. These fragments are then removed or allowed 
to pass spontaneously (4, 36, 37). 
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Ureteroscopy requires the use of an endoscope to visualize the urinary tract and 
collecting system. Ureteroscopes enable the use of other instruments to allow for stone 
fragmentation and removal (4, 37). 
Percutaneous nephrolithotomy is a procedure during which the surgeon makes a small 
incision in the patient’s back to remove the kidney stone using a hollow tube and a probe 
(4). Sometimes a laser is used to fragment the kidney stone. The fragments are then 
removed using basket extraction or a suction device (4, 37). 
2.6 Kidney stones in living kidney donors 
In a patient with a solitary kidney, the development of a kidney stone is potentially more 
serious. If the kidney stone obstructs the ureter, this usually requires an emergency 
surgical intervention to prevent acute renal failure (5). Literature has also demonstrated 
that kidney stones can result in a decline in renal function (38, 39). In an individual with 
one kidney, the consequences of this could potentially be more severe as they do not have 
a second kidney to compensate for the reduced renal function. 
On review of the literature, no risk estimates of kidney stones in living kidney donors 
were found. Instead the majority of the literature described donor-gifted lithiasis (5, 40-
45). This occurs when a stone is found in the donor kidney (either living or deceased) at 
the time of transplantation surgery. Normally the identified stone is removed immediately 
before transplantation into the recipient, or it is left as is if deemed small enough to not 
cause any complications to the recipient. However, all these studies only describe kidney 
stones which occurred prior to transplant, when the donor still had two kidneys. 
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 While the risk of kidney stones in living kidney donors has not been reported in 
literature, there have been case reports and discussions of treatment for kidney stones in 
individuals with a solitary kidney for any reason (46-51). One study comparing solitary 
and bilateral kidney patients being treated with percutaneous nephrolithotomy described 
individuals with a solitary kidney as having undergone significantly more procedures to 
remove kidney stones prior to the study (46). However, all of these studies focused on the 
method of treatment and did not provide estimates of the risk of kidney stones in 
individuals with a solitary kidney for any reason. 
2.7 Studying long-term outcomes of living kidney donors 
There are four major challenges to obtaining reliable estimates of the long-term risks 
associated with becoming a living kidney donor:  
1) Many donors do not reside close to a transplant centre, and their only purpose of 
visiting is to donate their kidney to the recipient. Beyond the first year after 
nephrectomy the majority of donors do not follow-up with the transplant centre. 
This makes it challenging to follow all donors for a given transplant centre over 
many years (where loss to follow-up can result in both selection biases and 
information biases).  
2) People experience health events as they age, and so when we observe such events 
in donors during follow-up it is questioned whether such events occurred due to 
aging and were unrelated to the donation process, or whether they are a biological 
consequence of nephrectomy. The only reliable way to solve this issue is to also 
study a non-donor ‘control’ group, where the rate of events observed in follow-up 
12 
 
can be compared between donors and non-donors to establish any true risk 
attributable to donation.  
3) Choosing the best type of non-donors to compare to the donors is central to any 
study of relative risks associated with donor nephrectomy (52). Donors go 
through a detailed selection process and are inherently healthier than the general 
population (53). Thus the ideal non-donor controls are those individuals who have 
a similar health state to donors at the time of nephrectomy.  
4) It may take years for biological changes from donation to manifest. To achieve 
such a long follow-up in a prospective study requires years of waiting and is an 
expensive proposition.  
The need for solutions to generate reliable information on long-term living donor 
outcomes was recently outlined in a State of the Art Conference with international 
opinion leaders (54). To address this need we are fortunate to have developed a unique 
cohort in Ontario, Canada. This cohort addresses the four challenges described above and 
its strengths are internationally recognized.  
2.9 Health administrative data in Ontario 
Ontario currently has approximately 13 million residents who have universal access to 
hospital and physician care (55). The province’s administrative healthcare databases 
provide a rich data source unique to Canada, which is representative of the entire 
province. Using these databases allows us to address weaknesses faced by prospective 
studies by minimizing selection and information biases, allowing for large sample sizes 
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and long periods of follow-up, as well as minimizing any loss-to-follow up (only due to 
emigration out of the province, <0.5% per year). 
In order to study the outcomes of living kidney donors, we manually reviewed the 
medical charts of over 2000 living kidney donors, and then linked this information to 
provincial healthcare databases housed at the Institute of Clinical Evaluative Sciences 
(ICES). We isolated the healthiest segment of the general population, providing us with a 
suitable non-donor comparison group.  
We have successfully leveraged this cohort in the past to provide much needed 
information on the risk of cardiovascular events, acute kidney injury with receipt of 
dialysis and fragility fractures in living kidney donors (published in the British Medical 
Journal (BMJ), Nephrology Dialysis Transplantation (NDT) and American Journal of 
Kidney Diseases (AJKD) respectively) (26-28). 
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3.1 Rationale 
We performed detailed searches of Pubmed, EMBASE and Google Scholar, and 
determined that there are no existing studies that evaluate the long-term risk of kidney 
stones in living kidney donors. When we expanded our search to include individuals with 
a solitary kidney for any reason, we still failed to find any description of the risk of these 
long-term outcomes (56).  
We did find some information on the treatment of kidney stones in patients with a single 
kidney. Individuals with a solitary kidney treated with percutaneous nephrolithotomy had 
less favourable outcomes compared to those with two kidneys (46).  Patients with a 
solitary kidney also underwent more procedures to remove kidney stones compared to 
those with two kidneys (46).  
There is no reason to suspect that living kidney donors would have a higher risk of 
kidney stones than members of the general population. Yet, a kidney stone in an 
individual with a solitary kidney can potentially obstruct the ureter, leading to acute renal 
failure and may result in urgent hospital attention and even surgical intervention.  This is 
also a concern because kidney stones can result in a decline in renal function, and this 
risk may be even higher in donors compared to non-donors (38, 39). 
Given the current state of the literature, the study we conducted is novel and meets an 
information need.  
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3.2 Research Question & Hypothesis 
We conducted this matched retrospective cohort study to determine if living kidney 
donors compared to healthy non-donors have a higher risk of: 1) kidney stones with 
surgical intervention, and 2) hospital encounters for kidney stones. 
Hypothesis: We expected that living kidney donors may be at greater relative risk for 
kidney stones with a surgical intervention compared to a group of healthy non-donors 
(where kidney stones which develop in follow-up will be less likely to result in an 
intervention). However, the absolute increase in risk will be low when compared to the 
control group of non-donors.  
 
 
 
17 
 
 
 
 
 
 
 
 
Chapter 4: Methods 
 
18 
 
4.1 Study design 
We conducted a matched retrospective cohort study using Ontario’s administrative 
healthcare databases held at the Institute for Clinical Evaluative Sciences (ICES).   
4.2 Data sources and data collection: Ontario healthcare databases  
The following databases were used to ascertain our variables of interest:  
The Trillium Gift of Life Network (TGLN) is Ontario’s central organ and tissue donation 
agency with information on kidney donors and recipients in Ontario. We used the TGLN 
database to identify living kidney donors, the main exposure group in this study. During 
the years 2008 to 2010 we manually reviewed each of the medical charts of over 2000 
living kidney donations which occurred between 1992 and 2009 at the five major 
transplant centres in Ontario. The five major transplant centres include London, Ottawa, 
Hamilton and the two centres in Toronto. I personally was responsible for reviewing all 
charts from the London, Ontario centre. The living donor information in the TGLN 
database is now complete, updated and accurate up to 2009.  
The Canadian Institute for Health Information Discharge Abstract Database, Same Day 
Surgery, and National Ambulatory Care Reporting System (CIHI-DAD, SDS, NACRS) 
databases collect demographic, diagnostic, and procedural variables for inpatient, 
emergency department and outpatient visits. Diagnostic and inpatient procedural coding 
uses the 9th version of the Canadian Modified International Classification of Disease 
system (ICD-9 CA) prior to 2002 and the 10th version (ICD-10 CA) thereafter. We used 
the CIHI datasets to identify the occurrence of kidney stones with surgical intervention. 
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We also used the datasets to identify any comorbid conditions which acted as exclusion 
criteria for the non-donor controls (see codes in Table 1).  
The Ontario Health Insurance Plan (OHIP) captures information on inpatient, outpatient, 
and laboratory services based on billing claims from Ontario physicians. In chart 
abstraction studies, agreement between abstracted OHIP codes and the actual codes the 
physicians recorded on the chart for the “most responsible” diagnosis was over 90% 
while agreement for procedural codes was over 88% (57). We used OHIP diagnostic 
codes to identify baseline conditions and both procedural and diagnostic codes to define 
our outcomes. 
The Registered Persons Database (RPDB) captures demographic information on Ontario 
residents including their sex, date of birth, postal code and vital status. We used the 
RPDB to ascertain baseline demographics, exclusion criteria and potential confounders. 
4.3 Cohort selection 
Kidney donors undergo a complete medical evaluation to ensure they are in excellent 
health prior to donation. In this study the date of nephrectomy was used as the date of 
cohort entry, and is also referred to as their index date. The accrual period was from July 
1st, 1992 to March 31st, 2012. To select a similar group of healthy non-donor controls, 
we first randomly assigned an index date to all adults in the population of Ontario, 
following the distribution of index dates in living kidney donors. For the control 
population we excluded all individuals who have evidence of a medical condition prior to 
their index date which would preclude them from becoming a living kidney donor (such 
as diabetes, hypertension or kidney disease). From the remaining controls we then 
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utilized a technique of matching, such that each donor was matched to ten non-donor 
controls based on index date (± 6 months), age (±  2 years), sex,  neighbourhood income 
quintile, and residential status (rural, urban). This process of: i) restricting the non-donor 
control sample to the healthiest segment of the population, and ii) matching donors and 
non-donors on key characteristics, represents our primary strategies to minimize 
confounding. Typically studies have demonstrated a limited increase in precision when 
the ratio of controls to cases is increased beyond four (58-60). However, given that our 
study was conducted using administrative data from the entire province of Ontario, it was 
feasible for us to obtain additional matched controls resulting in a slight increase in 
precision. 
We followed our donors and non-donor controls for outcomes of interest until March 
31st, 2012 (last date of follow-up). We have successfully used a similar technique to 
report the risk of cardiovascular events, acute kidney injury with dialysis and fracture 
outcomes in donors and non-donor controls (26-28). 
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Figure 1: Cohort selection flowchart for living kidney donors 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
LKD: Living Kidney Donor 
IKN: ICES Key Number 
All LKDs identified in TGLN 
between July 1992 and March 2009, 
from major transplant center 
(n=2083) 
Listed as LKD more than once (n=4) 
 
Donor IKN=Recipient IKN (n=9) 
 
Dialysis code from July 1991 to 4 
months after index date (n=13) 
 
Date of last contact <4 months after 
index date (n=15) 
 
Age <18 years at index date (n=1) 
 
Pregnant at time of donation (n=9) 
 
Evidence of kidney stones with surgical 
intervention/ hospital encounter for 
kidney stones (n=13) 
 
Included LKDs (n=2019) 
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Figure 2: Cohort selection flowchart for healthy non-donors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RPDB: Registered Persons Database 
IND: Index date  
DOLC: Date of Last Contact
All residents of Ontario 
registered in RPDB 
(n=71,792,616) 
Potential controls 
(n=13,461,161) given 
randomly assigned 
index date 
 
Date of death before July 12, 1992 (n=157,868) 
Age < 18 years on March 31, 2012 (n=3,743,913) 
Age > 75 years on July 12, 1992 (n=429,674) 
Potential controls 
(n=13,461,161) 
 
Date of death before IND (n=398,776) 
Age <18 on >75 on IND (n= 2,015,577) 
Death < 4 months after IND (n= 40,346) 
DOLC <4 months after IND (n= 1,041,351) 
Zero or >4 physician visits in 2 years prior to IND 
(n=8,143,158) 
Pregnant (<2 months prior and 6 months after) (n=8,610) 
 
Prior to IND: 
Diabetes (n=23,564) 
Hypertension (n=81,947) 
Cancer (n=45,752) 
Cardiovascular disease or surgery (n=30,478) 
Pulmonary disease (n=107,369) 
Liver disease (n=14,416) 
Systemic lupus erythematosus (n=45) 
Rheumatoid arthritis (n=278) 
HIV (n=49) 
Listed as kidney donor or recipient (n=444) 
Genitourinary disease (n=59,866) 
Nephrectomy (n=37) 
Renal biopsy (n=30) 
Dialysis (n=628) 
Nephrologist consultation (n=5,497) 
Gestational diabetes (n=374) 
Pre-eclampsia (n=3,710) 
 
 
Prior to and 7 days after IND: 
Kidney stones with surgical intervention (n=1,856) 
Other hospital encounters for kidney stones (n=2,564) 
 
 
 
 
 
Exclude: Include: 
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4.4 Study Population 
Donors were those individuals who donated a kidney at one of the five major adult 
transplant centers in Ontario.  
Our exclusion criteria for donors included the following: 
1) Evidence of kidney stones prior to index date (to ensure we capture only de novo 
events in follow-up: also the number of donors with a prior history of kidney 
stones is uncommon in our setting, and we cannot meaningfully look at this small 
group of patients). 
As mentioned above, non-donor controls must be in good health to ensure they are 
comparable to living kidney donors who undergo rigorous medical assessment in order to 
qualify for donation. To create an appropriate non-donor control group with similar 
health status to our donor group, we excluded all individuals from the general population 
with evidence of a contraindication to donation including the following:  
1) Any of the following conditions: Diabetes, hypertension, cancer, cardiovascular 
disease (including any heart disease, stroke or peripheral vascular disease), 
pulmonary disease, liver disease, systemic lupus erythematosus, rheumatoid 
arthritis, HIV, gestational diabetes, pre-eclampsia, kidney stones or any 
genitourinary disease renal disease (including a history of nephrectomy, kidney 
transplant, kidney biopsy, or dialysis) (53).  
2) Pregnant at the time of index date (ineligible to donate a kidney at that time). 
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3) Evidence of kidney stones with surgical intervention prior to the index date (as 
this same exclusion criteria is being used in our donor cohort). 
4.5 Outcome: Kidney stones with surgical intervention 
Our primary outcome was the evidence of kidney stones with surgical intervention 
following the index date until March 31st, 2012 (see Appendix 2 for codes). These codes 
have not been formally validated but are expected to have high sensitivity and specificity 
similar to other fee for service codes (61).  The codes were also chosen based on clinical 
expertise and an understanding of urology billing practices.  
All participants were followed up from index date until: i) death, ii) emigration from the 
province, or iii) the end of study period (March 31, 2012). Of the individuals who 
reached the end of the study (March 31, 2012), those whose most recent healthcare 
encounter was more than three years before the end of study (March 31, 2012) were 
classified as having emigrated from the province. These individuals were censored at one 
year following their last healthcare encounter. 
Outcomes include recurrent events (participants can have more than one occurrence of a 
kidney stone with surgical intervention during follow-up, but such interventions must be 
separated by at least 90 days to ensure it is an intervention for a new stone or 
reoccurrence of a stone).  
4.6 Data Analysis 
Descriptive Statistics and Baseline Characteristics: We described the continuous baseline 
characteristics as means with standard deviations for normally distributed data or as 
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medians with interquartile ranges for skewed data. We presented categorical variables as 
proportions. We assessed the differences between donors and non-donors using 
standardized differences (62). Standardized differences are less sensitive to sample size 
than traditional hypothesis tests. They provide a measure of the difference between 
groups divided by the pooled standard deviation, where a value greater than 10% is 
interpreted as a meaningful difference between the groups (62).  Our data sources and 
variables of interest were complete. In previous studies missing data has been < 1% (26-
28). 
Primary analyses: We used a negative binomial model stratified on matched sets to 
estimate the rate ratio and 95% confidence interval. This model also accounts for the 
possibility of a person having more than one stone event in follow-up (defined by events 
separated by at least 90 days). We repeated the primary analysis in three pre-specified 
subgroups defined by age (<40 vs ≥40 at index date), sex and index date (1992 to 2001 
[median follow-up 13.3 years, interquartile range (IQR) 11.4 to 15.8] vs. 2002 to 2009 
[median follow-up 5.9 years, IQR 4.3 to 7.8]).  
Additional analyses: We examined whether rate ratios differed among subgroups using a 
series of pair-wise standard z-tests. We repeated the primary analysis using Kaplan-Meier 
estimates stratified on matched sets to examine the first stone event in follow-up for both 
the primary and secondary outcomes. We examined the characteristics associated with 
stone events separately in donors and non-donors using negative binomial regression 
models. All analyses were performed at ICES with SAS software version 9.2 (SAS 
Institute, Cary, NC). 
26 
 
Table 1 provides sample size calculations based on α = 5%, 1 – β = 80%, an incidence of 
2.5% in non-donors, a 1:10 ratio of kidney donors to non-donors, and a continuity 
correction for the difference in proportions. Based on these calculations, we only required 
1515 donors and 15150 non-donors to detect an odds ratio of 1.5 over a median follow-up 
of 11 years, should an association exist. These are numbers well below our attained 
sample. 
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Table 1. Sample size calculations 
Presented are the number of individuals required in each group to detect a defined 
difference in the rate ratio should it in truth exist. 
 
Rate Ratio to be 
detected 
1.50 1.75 
1515 696 Living kidney donors 
15150 6960 Non-donor controls 
Assumptions: The proportion of non-donor controls who will develop a kidney stone over 
a median follow-up of 6 years is 2.5%. α = 0.05, 1-β = 0.8, a ratio of kidney donors to 
non-donor controls of 1:10. To simplify the calculations these analyses disregard the 
matching used to generate the sets and only consider the development of the first kidney 
stone in follow up. A continuity correction was used for the difference in proportions. 
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Chapter 5: Results 
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5.1 Baseline characteristics 
    Table 2 shows the baseline characteristics of the selected 2,019 donors and 20,190 
matched non-donors. Donors and non-donors had similar baseline characteristics. The 
median age at index date was 43 years (interquartile range 34 to 50) and median age at 
last follow-up was 52 years (interquartile range 44 to 60). Approximately 60% of the 
donor and non-donor cohorts were female, and 13% had a rural residency status. 
Approximately 62% of donors are first degree relatives of the recipient, with roughly 
35% donating to a sibling, 14% donating to a parent, and 13% donating to their child. 
The remaining living kidney donors donated to their spouse (20%), another relative (6%) 
or to an unrelated individual (12%). Donors had a median of 11 physician visits in the 
year prior to the index data, compared to a median of 1 physician visit in non-donors. 
This difference is expected, given the thorough medical work-up which is a necessary 
part of the donor evaluation process.   
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Table 2.  
Baseline characteristics of donors and healthy non-donors at the time of cohort entry. 
 Donors 
n = 2,019 
Non-donors 
n = 20,190 
Age, years 43 (34 – 50) 
 
43 (34 – 50) 
 Women 1,213 (60%) 12,130 (60%) 
Rural town 270 (13%) 2700 (13%) 
Income quintile 
         Lowest 
         Middle 
         Highest 
 
308 (15%) 
423 (21%) 
463 (23%) 
 
3,080 (15%) 
4,230 (21%) 
4,630 (23%) 
Physician visits in prior year* 11 (8 – 15) 1 (0 – 2) 
Year of cohort entry 
        1992 – 1997 
        1998 – 2003 
        2004 – 2009  
 
391 (19%) 
729 (36%) 
899 (45%) 
 
3915 (19%) 
7285 (36%) 
8990 (45%) 
Data presented as median (interquartile range) or as number (percent). The time of cohort entry is 
also referred to as the index date. This was the date of nephrectomy in donors and was randomly 
assigned to non-donors to establish the time follow-up began. 
*Indicates a standardized difference between donors and non-donors greater than 10%. As 
expected, donors had more physician visits in the year prior to index date compared to non-donors, 
as such visits are a necessary part of the donor evaluation process. 
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The median length of follow-up was 8.4 years (8.8 years in donors, 8.4 years in non-
donors, maximum 19.7 years). A total of 856 donors and 8,128 non-donors had over 10 
years of follow-up. The median age at the time of last follow-up for the entire cohort was 
52 years (interquartile range 44 to 60). Of the 22,209 individuals (2,019 donors, 20,190 
non-donors), 20,084 (90.4%) reached the end-of-study follow-up (March 31, 2012), 
1,499 (6.7%) were censored at emigration from the province, 480 (2.2%) were censored 
at the time of death and the remainder received at least one intervention for kidney 
stones. Total person years of follow-up were 204,199 (19,118 donors, 185,081 non-
donors).  
5. 2 Outcomes 
     The main outcomes are presented in Table 3 and Figures 3a and 3b. There were 195 
events of kidney stones with surgical intervention (16 in donors, 179 in non-donors). The 
rate of this event was no different in donors compared to non-donors (8.3 vs 9.7 events 
per 10,000 person-years; rate ratio, 0.85; 95% confidence interval (CI) 0.47-1.53). There 
were a total of 323 events of hospital encounters for kidney stones (23 in donors, 300 in 
non-donors) recorded in our data sources. The rate of this event was no different in 
donors compared to non-donors (12.1 vs 16.1 events per 10,000 person-years; rate ratio 
0.75; 95% CI 0.45-1.24). The results for both outcomes were the same when we assessed 
the time to first event (kidney stone with surgical intervention: hazard ratio 1.04, 95% CI 
0.60 – 1.80; hospital encounter for kidney stone: hazard ratio 0.81, 95% CI 0.51 – 1.30; 
see figures 3a and 3b for Kaplan-Meier curves).  
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Table 3. Primary and secondary outcome events among donors and non-donors. 
 Kidney stones with surgical intervention Hospital encounter for kidney stones 
 Donors  
(n=2,019) 
Non-donors 
(n=20,190) 
Donors  
(n=2,019) 
Non-donors 
(n=20,190) 
Median follow-up, years (IQR) 8.8 (5.6 – 12.9) 8.4 (5.3 – 12.6) 8.8 (5.6 – 12.9) 8.4 (5.3 – 12.6) 
Range follow-up, years (min, max) 0.55, 19.7 0.34, 19.7 0.55, 19.7 0.34, 19.7 
Total follow-up, person-years 19118 185080 19118 185080 
No. (%) of events:     
     0 2,005 (99%) 20,058 (99%) 2,000 (99%) 19,965 (99%) 
     1 12 (0.6%) 105 (0.5%) 15 (0.7%) 182 (0.9%) 
     2  ≤5* 12 (0.1%) ≤5* 23 (0.1%) 
   ≥3 ≤5* 15 (0.1%) ≤5* 20 (0.1%) 
No. of events per 10,000 person years 8.3 9.7 12.1 16.1 
Model based rate ratio † 0.85 (0.47 – 1.53) 1.00 (reference) 0.75 (0.45 – 
1.24) 
1.00 (reference) 
Data presented as number (percentage) or value (95% confidence interval) unless otherwise specified.  
IQR (interquartile range) 
*cell counts less than or equal to 5 have been suppressed for reasons of privacy. 
†p-values=0.58 and 0.27, respectively. 
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Figure 3a. Kaplan-Meier curve of time to first kidney stone with surgical intervention. 
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Figure 3b. Kaplan-Meier curve of time to first hospital encounter for a kidney stone. 
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 Subgroup analyses are shown in Figures 4a and 4b. Older age at study enrolment, sex, 
and earlier date of enrolment (longer follow-up) did not influence the association between 
living kidney donation and risk of kidney stones with surgical intervention (p value for 
interaction ranged from 0.40 – 0.80). Subgroup results were similar for the secondary 
outcome of hospital encounters of kidney stones, with one exception: the rate ratio 
between living donation and outcome was lower in men compared to women. In the 
subgroup of men donors had a lower (not higher) risk of the outcome than non-donors.   
         When donors and non-donors were examined separately, the 95% confidence 
intervals of risk factor rate ratios were more precise in non-donors (expected as there 
were 10 times as many non-donors as donors).  In donors, no significant associations 
were observed between various risk factors (age, sex, rural residence, income quintile, 
and year of index date) and the primary or secondary outcomes (Table 4). In non-donors, 
older age and male sex were associated with an increased risk of kidney stones with 
surgical intervention and hospital encounters for kidney stones.  
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Figure 4a. Influence of age, sex, & index date (length of follow-up) on primary outcome of kidney stones with surgical intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
*Individuals with index date of 1992-2001 had median follow up of 13.3 years, interquartile range (IQR) 11.7 to 16.0; individuals with index date of 2002-2009 had median 
follow-up of 5.9 years, IQR 4.3 to 7.8. 
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Figure 4b. Influence of age, sex, & index date (length of follow-up) on secondary outcome of hospital encounters for kidney stones. 
 
 
 
 
 
 
 
 
 
 
 
 
*Individuals with index date of 1992-2001 had median follow up of 13.3 years, interquartile range (IQR) 11.7 to 16.0; individuals with index date of 2002-2009 had median 
follow-up of 5.9 years, IQR 4.3 to 7.8. 
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Table 4. Risk factors for kidney stones in donor and non-donors when each group was analyzed separately.  
 
 Donors Non-donors 
Kidney stones with surgical intervention 
Older age (per 5 years) 1.15 (0.90 – 1.50) 1.12 (1.02 – 1.23) 
Women (vs. men) 0.92 (0.30 – 2.85) 0.49 (0.34 – 0.73) 
Rural residence (vs. urban residence) 2.49 (0.29 – 21.65) 1.04 (0.59 – 1.84) 
Higher income quintile 0.87 (0.59 – 1.29) 0.95 (0.82 – 1.10) 
More recent year of index date 
 
0.97 (0.85 – 1.11) 0.99 (0.94 – 1.04) 
Hospital encounters for kidney stones 
Older age (per 5 years) 1.02 (0.82 – 1.26) 1.08 (1.01 – 1.15) 
Women (vs. men) 1.60 (0.56 – 4.58) 0.46 (0.34 – 0.61) 
Rural residence (vs. urban residence) 1.74 (0.33 – 9.06) 1.08 (0.70 – 1.67) 
Higher income quintile 1.00 (0.70 – 1.43) 0.92 (0.82 – 1.02) 
More recent year of index date 1.01 (0.91 – 1.13) 0.98 (0.95 – 1.02) 
Separate negative binomial models were created for donors and non-donors. Presented are the rate ratios and 95% 
confidence intervals. 
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Chapter 6: Discussion 
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6.1 Overview of findings 
We hypothesized that a donor with one kidney might receive surgical intervention for a 
stone more frequently than a non-donor with two kidneys presenting with a stone. 
Similarly, we expected that donors with stones might be more likely to present to 
hospital. However, our findings do not support these hypotheses. In this study, we 
determined that the rates of 1) kidney stones with surgical intervention, and 2) hospital 
encounters for kidney stones, were not significantly different between donors and non-
donors. The majority of living kidney donors (99.3%) did not experience a kidney stone 
intervention or hospital encounter over a median follow-up of 8.8 years (maximum 
follow-up 19.7 years). There was also no evidence that donation increased the risk of 
either kidney stone event when examined in subgroups defined by age, sex, or index date 
(length of follow-up). The Kaplan-Meier curves after 10 years of follow-up did not 
suggest any higher risk of stone events in donors compared to non-donors.  
When non-donors were examined using a separate negative binomial model, both older 
age, and male sex were associated with an increased risk of kidney stones with surgical 
intervention, and hospitalization for kidney stones. This finding is consistent with 
previous literature, which has established age and male sex as known risk factors for 
kidney stones (29, 31). We did not find this to be the case within the donor cohort when 
analyzed separately, though we did expect these risk factors to behave similarly. 
However, this can be explained by the limited number of kidney stone events within the 
donor cohort, preventing us from reliably assessing these risk factors in the separate 
analysis. 
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Overall, these findings are reassuring towards the practice of living kidney donation. It 
demonstrates the effectiveness of the thorough screening that donors undergo prior to 
donation. 
6. 2 Strengths 
Our study has a number of strengths. To our knowledge this is the first study to report on 
a donor’s long-term risk of kidney stones after living kidney donation. The universal 
healthcare benefits available to all Ontario residents allowed us to efficiently study all 
living donation activity in the largest province of Canada, minimizing both information 
and selection biases. We ensured the accuracy of donor data captured in the Trillium Gift 
of Life database through the manual review of over 2000 pre-donation medical charts at 
the five major transplant centres in Ontario. We addressed potential confounders by 
matching donors and non-donors on risk factors associated with kidney stone events such 
as older age and male sex (29, 31). Loss to follow-up, which is a concern in most long-
term donor studies, was minimal in our study with less than 7% censored in follow-up at 
the time of emigration from the province.  
6.3 Limitations 
     Our study does have some limitations.  The retrospective nature of the study prevented 
us from controlling the assessment of the exposure and outcome, meaning we relied on 
administrative data collected for non-research purposes. The use of administrative data 
limited us with regards to: the types of data and variables that were available to us, how 
we ascertained our outcomes, and our inclusion and exclusion criteria for the selection of 
the donor and healthy non-donor cohorts.  
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Our administrative data sources also prevented us from addressing some potential 
confounders. We had no baseline or follow-up information in our data sources on dietary 
risk factors for stones such as water intake, salt consumption and calcium 
supplementation (2, 63). We did not take other known risk factors for kidney stones 
including race and Body Mass Index (BMI) into account because they could not be 
accurately ascertained using our data sources. However, given that 75% of the Ontario 
population is Caucasian, we expect our results to generalize well to Caucasian donors but 
not to other races. Previous literature has observed a higher prevalence of kidney stones 
in American Caucasians when compared to African Americans and Hispanics in the 
United States (64). Additionally, given Ontario’s relatively uniform climate, the observed 
rates would not be comparable to regions within the kidney stone belt which are typically 
higher because of elevated temperatures.   
Unlike the donors, most non-donors did not have routine imaging to rule out the presence 
of baseline asymptomatic kidney stones. Residual confounding, which is inherent to any 
observational study, may affect the association between living kidney donation and the 
outcome of interest seen in our study.  
We relied on clinical expertise and knowledge of billing practices to define our outcomes, 
as the codes were either not validated or partially validated. There are no reliable codes to 
detect kidney stones that do not present to hospital attention. Also, codes to detect kidney 
stones presenting to hospital are insensitive and underestimate the true incidence of the 
event.(65) However, this is not the case for kidney stones requiring surgical intervention 
and we do not anticipate coding inaccuracies in stones presenting to hospital were 
differential between donors and non-donors (i.e. estimates of relative risk are valid). 
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6.4 Future Directions 
While these findings are reassuring for the practice of living kidney donation, it is 
possible that the risk may take longer to manifest. In order to fully understand the long-
term risk of kidney stones with surgical intervention in living kidney donors, we will 
continue to follow our cohort in order to obtain several additional decades of follow-up.  
While living kidney donation is the preferred treatment option for individuals living with 
renal failure, the supply still does not meet the growing demand for organs. In order to 
address this discrepancy, efforts are being made to increase the number of living 
donations through the acceptance of expanded criteria donors. Expanded criteria donors 
are donors who may not meet the strict donation criteria, but are deemed sufficiently 
healthy enough to donate. Having a history of kidney stones was once a contraindication 
to becoming a living kidney donor. However, this criterion has become more relaxed in 
recent years. Our study does not provide evidence regarding the safety of this practice, as 
we assessed the de novo formation of kidney stones. Additionally these results should not 
be used to justify expansion of donor eligibility to those with risk factors for stones, such 
as obesity or a prior history of stones (3, 31, 66). Rather, this is only the first step in 
understanding the risk to expanded criteria donors. We have simply established that the 
baseline risk of kidney stone events in donors selected using the strict standard criteria is 
no different than in healthy non-donors. Further studies, following donors with a history 
of kidney stones, are needed to establish whether it is safe for such individuals to become 
donors. 
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In addition, future studies can assess the risk of any kidney stone event, not simply those 
requiring hospital encounters or surgical intervention. This would first require the 
validation of the ICD-9 and ICD-10 codes for diagnosis of kidney stones in order to 
accurately assess the risk of these events using administrative healthcare databases. 
However, a prospective cohort study would be the optimal method to ascertain a living 
kidney donor’s risk of developing kidney stones post-donation. This would allow 
additional important confounders like diet, race, BMI, and family history of kidney 
stones to be addressed (32, 66, 67). Imaging could be performed on participants to 
identify the formation of asymptomatic kidney stones as well. 
6.5 Conclusion 
Through this study we have determined that the risks of 1) kidney stones with surgical 
intervention, and 2) hospital encounters for kidney stones are no different between living 
kidney donors and matched healthy non-donors. As we continue to follow this study 
cohort, these interim findings are reassuring to the safety of the practice of living kidney 
donation. 
45 
 
References 
 
1. Horvat LD, Shariff SZ, Garg AX. Global trends in the rates of living kidney 
donation. Kidney international. 2009;75(10):1088-98.  
2. Pak CY. Kidney stones. Lancet. 1998;351(9118):1797-801.  
3. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 
2006;367(9507):333-44.  
4. Miller NL, Lingeman JE. Management of kidney stones. BMJ. 
2007;334(7591):468-72.  
5. Rashid MG, Konnak JW, Wolf JS, Jr., Punch JD, Magee JC, Arenas JD, et al. Ex 
vivo ureteroscopic treatment of calculi in donor kidneys at renal transplantation. The 
Journal of urology. 2004;171(1):58-60.  
6. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80.  
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new prediction 
equation. Modification of Diet in Renal Disease Study Group. Annals of internal 
medicine. 1999;130(6):461-70.  
8. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured 
and estimated glomerular filtration rate. The New England journal of medicine. 
2006;354(23):2473-83.  
9. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global 
overview of patient numbers, treatment modalities and associated trends. Nephrology, 
dialysis, transplantation : official publication of the European Dialysis and Transplant 
Association - European Renal Association. 2005;20(12):2587-93.  
10. CIHI. Canadian Organ Replacement Register Annual Report: Treatment of End-
Stage Organ Failure in Canada, 2000 to 2009. Ottawa, ON: CIHI, 2011. 
11. Pastan S, Bailey J. Dialysis therapy. The New England journal of medicine. 
1998;338(20):1428-37.  
12. Oniscu GC, Brown H, Forsythe JL. How great is the survival advantage of 
transplantation over dialysis in elderly patients? Nephrology, dialysis, transplantation : 
official publication of the European Dialysis and Transplant Association - European 
Renal Association. 2004;19(4):945-51.  
46 
 
13. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal 
disease patients. American journal of kidney diseases : the official journal of the National 
Kidney Foundation. 2001;38(3):443-64.  
14. Dew MA, Switzer GE, Goycoolea JM, Allen AS, DiMartini A, Kormos RL, et al. 
Does transplantation produce quality of life benefits? A quantitative analysis of the 
literature. Transplantation. 1997;64(9):1261-73.  
15. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. 
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting 
transplantation, and recipients of a first cadaveric transplant. The New England journal of 
medicine. 1999;341(23):1725-30.  
16. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic 
review: kidney transplantation compared with dialysis in clinically relevant outcomes. 
American journal of transplantation : official journal of the American Society of 
Transplantation and the American Society of Transplant Surgeons. 2011;11(10):2093-
109.  
17. Murray J. Interview with Dr Joseph Murray (by Francis L Delmonico). American 
journal of transplantation : official journal of the American Society of Transplantation 
and the American Society of Transplant Surgeons. 2002;2(9):803-6.  
18. Matas AJ, Bartlett ST, Leichtman AB, Delmonico FL. Morbidity and mortality 
after living kidney donation, 1999-2001: survey of United States transplant centers. 
American journal of transplantation : official journal of the American Society of 
Transplantation and the American Society of Transplant Surgeons. 2003;3(7):830-4.  
19. Gridelli B, Remuzzi G. Strategies for making more organs available for 
transplantation. The New England journal of medicine. 2000;343(6):404-10.  
20. Knoll GA, Nichol G. Dialysis, kidney transplantation, or pancreas transplantation 
for patients with diabetes mellitus and renal failure: a decision analysis of treatment 
options. Journal of the American Society of Nephrology : JASN. 2003;14(2):500-15.  
21. Klarenbach S, Garg AX, Vlaicu S. Living organ donors face financial barriers: a 
national reimbursement policy is needed. CMAJ : Canadian Medical Association journal 
= journal de l'Association medicale canadienne. 2006;174(6):797-8.  
22. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-
term implications. Journal of the American Society of Nephrology : JASN. 2002;13 
Suppl 1:S37-40.  
23. CIHI. Number of Canadians living with kidney failure triples over 20 years: 
Renal transplantation saving millions in dialysis costs2011 January 14, 2012. Available 
from: http://www.cihi.ca/CIHI-ext-
portal/internet/en/Document/types+of+care/specialized+services/organ+replacements/RE
LEASE_20JAN11. 
47 
 
24. Clemens KK, Thiessen-Philbrook H, Parikh CR, Yang RC, Karley ML, Boudville 
N, et al. Psychosocial health of living kidney donors: a systematic review. American 
journal of transplantation : official journal of the American Society of Transplantation 
and the American Society of Transplant Surgeons. 2006;6(12):2965-77.  
25. Ommen ES, Winston JA, Murphy B. Medical risks in living kidney donors: 
absence of proof is not proof of absence. Clinical journal of the American Society of 
Nephrology : CJASN. 2006;1(4):885-95.  
26. Garg AX, Pouget J, Young A, Huang A, Boudville N, Hodsman A, et al. Fracture 
risk in living kidney donors: a matched cohort study. American journal of kidney diseases 
: the official journal of the National Kidney Foundation. 2012;59(6):770-6.  
27. Garg AX, Meirambayeva A, Huang A, Kim J, Prasad GV, Knoll G, et al. 
Cardiovascular disease in kidney donors: matched cohort study. BMJ. 2012;344:e1203.  
28. Lam N, Huang A, Feldman LS, Gill JS, Karpinski M, Kim J, et al. Acute dialysis 
risk in living kidney donors. Nephrology, dialysis, transplantation : official publication of 
the European Dialysis and Transplant Association - European Renal Association. 
2012;27(8):3291-5.  
29. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of 
prevalence, incidence, and associated risk factors. Reviews in urology. 2010;12(2-3):e86-
96.  
30. Lukienko PI, Mel'nichenko NG, Zverinskii IV, Zabrodskaya SV. Antioxidant 
properties of thiamine. Bulletin of experimental biology and medicine. 2000;130(9):874-
6.  
31. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in 
reported prevalence of kidney stones in the United States: 1976-1994. Kidney 
international. 2003;63(5):1817-23.  
32. Parmar MS. Kidney stones. BMJ. 2004;328(7453):1420-4.  
33. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary 
calcium and other nutrients and the risk of symptomatic kidney stones. The New England 
journal of medicine. 1993;328(12):833-8.  
34. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT. Renal stone 
epidemiology: a 25-year study in Rochester, Minnesota. Kidney international. 
1979;16(5):624-31.  
35. Hiatt RA, Dales LG, Friedman GD, Hunkeler EM. Frequency of urolithiasis in a 
prepaid medical care program. American journal of epidemiology. 1982;115(2):255-65.  
36. Srisubat A, Potisat S, Lojanapiwat B, Setthawong V, Laopaiboon M. 
Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy 
48 
 
(PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. The Cochrane 
database of systematic reviews. 2009(4):CD007044.  
37. Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck AC, Gallucci M, et al. 
2007 Guideline for the management of ureteral calculi. European urology. 
2007;52(6):1610-31.  
38. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S, et al. 
Kidney stones and kidney function loss: a cohort study. BMJ. 2012;345:e5287.  
39. Rule AD, Bergstralh EJ, Melton LJ, 3rd, Li X, Weaver AL, Lieske JC. Kidney 
stones and the risk for chronic kidney disease. Clinical journal of the American Society 
of Nephrology : CJASN. 2009;4(4):804-11.  
40. Kumar A, Das SK, Srivastava A. Expanding the living related donor pool in renal 
transplantation: use of marginal donors. Transplantation proceedings. 2003;35(1):28-9.  
41. Strang AM LM, Burns JR, Amling CL, Kolettis PN. Short term outcomes of 
living donor allograft nephrolithiasis in renal transplant donors and recipients. The 
Journal of urology. 2007;177(4, Suppl. S).  
42. Martin G, Sundaram CP, Sharfuddin A, Govani M. Asymptomatic urolithiasis in 
living donor transplant kidneys: initial results. Urology. 2007;70(1):2-5; discussion -6.  
43. Ganpule A, Vyas JB, Sheladia C, Mishra S, Ganpule SA, Sabnis RB, et al. 
Management of urolithiasis in live-related kidney donors. Journal of endourology / 
Endourological Society. 2013;27(2):245-50.  
44. Olsburgh J, Thomas K, Wong K, Bultitude M, Glass J, Rottenberg G, et al. 
Incidental renal stones in potential live kidney donors: prevalence, assessment and 
donation, including role of ex vivo ureteroscopy. BJU international. 2013;111(5):784-92.  
45. Stravodimos KG, Adamis S, Tyritzis S, Georgios Z, Constantinides CA. Renal 
transplant lithiasis: analysis of our series and review of the literature. Journal of 
endourology / Endourological Society. 2012;26(1):38-44.  
46. Bucuras V, Gopalakrishnam G, Wolf JS, Jr., Sun Y, Bianchi G, Erdogru T, et al. 
The Clinical Research Office of the Endourological Society Percutaneous 
Nephrolithotomy Global Study: nephrolithotomy in 189 patients with solitary kidneys. 
Journal of endourology / Endourological Society. 2012;26(4):336-41.  
47. Kupajski M, Tkocz M, Ziaja D. Modern management of stone disease in patients 
with a solitary kidney. Wideochirurgia i inne techniki malo inwazyjne = Videosurgery 
and other miniinvasive techniques / kwartalnik pod patronatem Sekcji Wideochirurgii 
TChP oraz Sekcji Chirurgii Bariatrycznej TChP. 2012;7(1):1-7.  
48. Wang Y, Hou Y, Jiang F, Wang C. Percutaneous nephrolithotomy for staghorn 
stones in patients with solitary kidney in prone position or in completely supine position: 
49 
 
a single-center experience. International braz j urol : official journal of the Brazilian 
Society of Urology. 2012;38(6):788-94.  
49. Huang Z, Fu F, Zhong Z, Zhang L, Xu R, Zhao X. Chinese minimally invasive 
percutaneous nephrolithotomy for intrarenal stones in patients with solitary kidney: a 
single-center experience. PloS one. 2012;7(7):e40577.  
50. Pejcic T, Markovic B, Djurasic L, Maksimovic H, Topuzovic C, Dzamic Z, et al. 
The dissolution of multiple renal uric acid stones via percutaneous nephrostomy in the 
patient with a solitary kidney. Acta chirurgica Iugoslavica. 2012;59(3):93-6.  
51. Heimbach D, Wirth M, Hofmockel G, Frohmuller H. Are auxiliary methods 
necessary prior to ESWL in patients with a solitary kidney? Urologia internationalis. 
1994;52(3):131-4.  
52. Lin J. KH, Chandraker A. K. Mortality among living kidney donors and 
comparison populations. The New England journal of medicine. 2010;363:797-8.  
53. Delmonico F. A Report of the Amsterdam Forum On the Care of the Live Kidney 
Donor: Data and Medical Guidelines. Transplantation. 2005;79(6 Suppl):S53-66.  
54. Leichtman A, Abecassis M, Barr M, Charlton M, Cohen D, Confer D, et al. 
Living kidney donor follow-up: state-of-the-art and future directions, conference 
summary and recommendations. American journal of transplantation : official journal of 
the American Society of Transplantation and the American Society of Transplant 
Surgeons. 2011;11(12):2561-8.  
55. StatsCanada. Table   051-0005 -  Estimates of population, Canada, provinces and 
territories, quarterly (persons). 2011. 
56. Hegde S, Coulthard MG. Renal agenesis and unilateral nephrectomy: what are the 
risks of living with a single kidney? Pediatr Nephrol. 2009;24(3):439-46.  
57. Goel V WJ, Anderson G, Blackstien-Hirsh P, Fooks C, Naylor D. Patterns of 
Health Care in Ontario. 2nd Edition. 1996.  
58. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control 
studies. Lancet. 2005;365(9468):1429-33.  
59. Ury HK. Efficiency of case-control studies with multiple controls per case: 
continuous or dichotomous data. Biometrics. 1975;31(3):643-9.  
60. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in 
case-control studies. III. Design options. American journal of epidemiology. 
1992;135(9):1042-50.  
61. Williams  JI, & Young, W. A summary of studies on the quality of health care 
administrative databases in Canada. . In: Goel V WJ, Anderson GM, Blacksterin-Hirsch 
50 
 
P, Fooks C, Naylor CD, editor. Patterns of Health Care in Ontario: The ICES Practice 
AtlasOttawa: Canadian Medical Association1996. p. 339-45. 
62. Austin PC. Using the standardized difference to compare the prevalence of a 
binary variable between two groups in observational research. Communications in 
Statistics – Simulation and Computation. 2009;38:1228-34.  
63. Sorensen MD, Kahn AJ, Reiner AP, Tseng TY, Shikany JM, Wallace RB, et al. 
Impact of nutritional factors on incident kidney stone formation: a report from the WHI 
OS. The Journal of urology. 2012;187(5):1645-9.  
64. Goldfarb DS. Increasing prevalence of kidney stones in the United States. Kidney 
international. 2003;63(5):1951-2.  
65. Scales CD, Jr., Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in 
the United States. European urology. 2012;62(1):160-5.  
66. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk 
of kidney stones. Journal of the American Society of Nephrology : JASN. 
1998;9(9):1645-52.  
67. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of 
kidney stones. Journal of the American Society of Nephrology : JASN. 1997;8(10):1568-
73.  
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Appendix A: Checklist of recommendations for reporting of observational studies 
using the STROBE (STrengthening the Reporting of OBservational studies in 
Epidemiology) guidelines. 
 
Item 
No Recommendation 
Reported  
Title and abstract 1 
(a) Indicate the study’s design with a commonly 
used term in the title or the abstract 
abstract 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
abstract 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for 
the investigation being reported 
introduction 
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
introduction 
Methods  
Study design 4 Present key elements of study design early in the 
paper 
methods 
Setting 5 
Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
methods 
Participants 6 
(a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe 
methods of follow-up 
methods 
(b)For matched studies, give matching criteria and 
number of exposed and unexposed 
methods 
Variables 7 
Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
methods 
Data sources/ 
measurement 
8 
For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one group 
methods 
Bias 9 Describe any efforts to address potential sources of 
bias 
methods 
Study size 10 Explain how the study size was arrived at methods 
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Quantitative variables 11 
Explain how quantitative variables were handled in 
the analyses. If applicable, describe which 
groupings were chosen and why 
methods 
Statistical methods 
 
12 
(a) Describe all statistical methods, including those 
used to control for confounding 
methods 
(b) Describe any methods used to examine 
subgroups and interactions 
methods 
(c) Explain how missing data were addressed not applicable 
(d) If applicable, explain how loss to follow-up was 
addressed 
not applicable 
(e) Describe any sensitivity analyses not applicable 
 
(Continued on next page) 
Results 
 
Participants 13 
(a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
Methods, results 
(b) Give reasons for non-participation at each stage methods 
(c) Consider use of a flow diagram methods 
Descriptive data 14 
(a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 
exposures and potential confounders 
table 1 
(b) Indicate number of participants with missing 
data for each variable of interest 
not applicable 
(c) Summarise follow-up time (e.g. average and 
total amount) 
table 2 
Outcome data 15 Report numbers of outcome events or summary 
measures over time 
results, table 2 
Main results 16 
(a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g. 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
results, table 2 
(b) Report category boundaries when continuous 
variables were categorized 
table 1 
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(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
not applicable 
Other analyses 17 Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity analyses 
Results, table 3 
Discussion  
Key results 18 Summarise key results with reference to study 
objectives 
discussion 
Limitations 19 
Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
discussion 
Interpretation 20 
Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
discussion 
Generalisability 21 Discuss the generalisability (external validity) of 
the study results 
discussion 
Other information  
Funding 22 
Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
acknowledgements 
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Appendix B: Kidney stone codes 
KIDNEY STONE WITH SURGICAL INTERVENTION 
OHIP fee codes CCI CCP 
Z630 (Extracorporeal shock wave 
lithotripsy) 
 
E773 (Stent with stone) 
 
Z629 (perinephrium percutaneous 
nephrostomy) 
 
Z623 (Kidney, perinephrium  insertion of 
stent) 
 
J046 (Diagnostic radiology, percutaneous 
nephrostomy) 
 
Z624 (Kidney perinephrium dilation of 
tract) 
 
Z627 (Kidney-removal of renal calculi) 
 
E759 (Disintegrated by US. add to 
removal renal calculi) 
 
E772 (Percut rem. staghorn calc. renal 
pelvis, add) 
 
Z628 (Ureteroscopy/cystoscopy above 
intramural ureter) 
 
E760 (Ureter-removal of stone add  cysto 
& ureteroscopy) 
 
E761 (Ureter-if disintegrat.by US add to 
cysto & ureterosc.) 
 
Z627 (Kidney-removal of renal calculi) 
 
S430 (Kidney-litholapaxy-staghorn 
calculus,incl. X-ray) 
 
S405 (Nephrolithotomy) 
 
S408 (Pyelolithotomy) 
Stone Destruction 
1pe59  
(renal pelvic, 
ureteropelvic junction) 
 
1pg59  
(ureter, ureterovesical 
junction) 
 
1pm59  
(urinary stoma, cystomy, 
nephrostomy, 
ureterostomy) 
 
1pv59  
(surgically created 
urinary tract) 
 
 
Stone Extraction 
1pe57  
(renal pelvic, 
ureteropelvic junction) 
 
1pg57  
(ureter, ureterovesical 
junction) 
 
1pm57  
(urinary stoma, cystomy, 
nephrostomy, 
ureterostomy) 
 
1pv57  
(surgically created 
urinary tract) 
67.03  
(percutaneous 
nephrostomy 
without 
fragmentation) 
 
67.04  
(percutaneous 
nephrostomy 
with 
fragmentation) 
 
68.95  
(ureteroscopy) 
 
71.96  
(ultrasonic stone 
fragmentation) 
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S445 (ureterotomy removal of calculus 
upper 2/3) 
 
S446 (ureterotomy removal of calculus 
lower 1/3) 
 
NON-SURGICAL HOSPITAL ENCOUNTERS FOR KIDNEY STONES 
ICD-9: 592, 592.0, 592.1, 592.9 
ICD-10: N20 
CCI: Canadian Classification of Health Interventions; CCP: Canadian Classification of Diagnostic, Therapeutic, and 
Surgical Procedures 
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Appendix C: Data Creation Plan 
Risk of kidney stones with surgical intervention in living kidney donors 
Study number 2013 0906 010 000 
Research 
program 
Kidney, Dialysis, Transplantation (KDT) 
Contacts Sonia Thomas  
Anjie Huang  
Amit Garg 
Ngan Lam 
Danielle Nash 
Blayne Welk  
Ramesh Prasad  
Krista Lentine 
Updates by Sonia Thomas 
PIA approved? Yes 
DCP update 
history 
Version 1: October 29, 2012 (ST) 
Version 2: November 13, 2012 (ST, after meeting with AG) 
Version 3: November 16, 2012 (ST) 
Version 4: November 19, 2012 (after call with AH, AG) 
Version 5: November 28, 2012 (ST) 
Version 6: December 17, 2012 (ST) 
 
Research 
question 
To examine the long-term risk of kidney stones with intervention following living 
kidney donation. The study will include all living kidney donors in the province of 
Ontario who donated a kidney between July 1, 1992 and March 31, 2009. We will 
compare the risk of kidney stones with intervention in LKD to healthy non-donor 
controls. 
Study design Retrospective cohort study 
 
List of datasets 
used 
 
1. Trillium Gift of Life Network (TGLN) [July 1992 – March 2009] 
TGLN data 
dictionary.doc
 
2. Ontario Diabetes Database (ODD) [July 1991 – March 2009] 
 
3. Ontario Hypertension Database (OHD) [July 1991 – March 2009] 
 
4. CIHI-DAD and CIHI-SDS [July 1991 – March 2012] 
Source 
 All 
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Institution types 
 All 
 
5. NACRS [July 2000 – March 2012] 
Source 
 ED 
Include planned visits 
 Yes  
 
6. Ontario Health Insurance Plan (OHIP) [July 1991 – March 2012] 
Code Types 
 Feecodes 
 
 [see Appendices A, B, C, D, E embedded in exclusion criteria section for 
codes] 
7. Registered Persons Database (RPDB) [July 1991 – March 2012] 
 
Defining the cohort 
Index date Date of kidney donation in TGLN (LIVING_DONORS_ENC.TX_DATE) 
Inclusion 
criteria 
Retrospective cohort study comparing 2 groups: 
 
Exposed: Individuals who have undergone living kidney donation and meet the 
following requirements: 
- Donated between July 1, 1992 and March 31, 2009 with a valid IKN  
   (LIVING_DONORS_ENC.valikn = ‘V’) 
- Donation at a study eligible transplant center 
(LIVING_DONORS_ENC.TX_HOSP_OTTAWA HOSPITAL GENERAL 
CAMPUS; OTTAWA HOSPITAL CIVIC CAMPUS; ST JOSEPH'S 
HEALTHCARE  SYSTEM – HAMILTON, ST MICHAEL'S HOSPITAL – 
[Toronto], TORONTO GENERAL HOSPITAL, UNIVERSITY HOSPITAL - 
[London] ). In other words the hospitals excluded from the analysis are: 
KINGSTON GENERAL HOSPITAL, THE HOSPITAL FOR SICK 
CHILDREN) 
 
Non-exposed: Individuals from the general population matched to the exposed 
group (Medically eligible to donate a kidney, see “Exclusion Criteria”) 
 
Cohort size Anticipate approximately 2000 living kidney donors and 20,000 matched non-
donor controls (1:10 match ratio) 
 
Exclusion criteria 
Exclusion 
criteria for 
DONORS  
(in order) 
(See Table 1) 
 
Data cleaning steps 
 
   Exclude if: 
1) Missing DOB in RPDB (expect this will be close to 0) 
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2) Missing gender in RPDB (expect this will be close to 0) 
3) Listed as living kidney donor more than once in TGLN dataset 
 
4) Donor id = recip id  or don_ikn=recip_ikn;   
this is either in i) Trillium sources OR ii) when linked to RPDB (note: 
appreciate this will remove the rare donor who develops ESRD and then 
requires a transplant; guarding against possibility out-of-province donor, 
etc. received services under recipient OHIP number). 
 
5)  ≥ 1 dialysis code from Appendix A (CIHI or OHIP code) from July 1st, 
1991 to 4 months after index date (rationale: this is being done to exclude 
any recipient who has been miscoded as a living kidney donor; appreciate 
this will remove any donor who required dialysis within 4 months of 
donation – a very rare event).  
 
6) Missing date of nephrectomy (missing 
LIVING_DONORS_ENC.TX_DATE; expect this to be 0 as this was used 
to construct dataset)  
 
7) Date of death in RPDB is before index date 
 
8) Date of death in RPDB < 4 months AFTER index date (rationale: this is 
being done to exclude any deceased kidney donor who has been miscoded 
as a living kidney donor. Appreciate this exclusion will result in “immortal 
time” for anyone left in the analysis (i.e. no chance of death between index 
date and four months after donation; rate of death is so exceedingly rare 
this is not an issue).  
 
9)  Date of Last Contact (DOLC) is < 4 months AFTER index date (rationale: 
this is being done to exclude any out of province living kidney donors; by 
convention it would also result in the exclusion of any deaths in 4 months after 
donation, but this exclusion is being applied after the death exclusion above. By 
applying this exclusion we are restricting the analysis to those individuals who 
have ≥ 1 Ontario health care contact ≥ 4 months after donation).  
10)  Age <18 at index date 
 
11)  Age > 75 at index date 
 
 
12)  Pregnant at the time of index date (defined by evidence of ≥ 1 birth code, in 2 
months prior to index date to 6 months after index date; birth codes presented in 
Appendix B) 
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13) Evidence of kidney stones with surgical intervention prior to the index date 
and 7 days after index date (codes presented in Appendix D) 
     
 
14) Evidence of other hospital encounters for kidney stones prior to the index 
date and 7 days after index date (codes presented in Appendix E) 
               
 
Exclusion 
criteria for 
CONTROLS 
(in order) 
(See Table 1a 
and 1b) 
 
See Appendix C for control exclusion criteria codes, and “Outline of Analysis 
Plan” section for description of method to select control subjects. 
 
Data cleaning steps 
   Exclude if: 
1) Invalid IKN 
2) Missing gender in RPDB 
3) Missing date of birth in RPDB 
4) Date of death in RPDB before July 12, 1992  
(1st date of transplant in TGLN database) 
5) Age <18 on March 31, 2009 
6) Age >75 on January 1, 1992 
 
*ASSIGN INDEX DATE* 
 
Exclude if any of the following: 
(from July 1991,  up to but not including the index date) 
 
7) Date of death in RPDB is before randomly assigned index date 
8) Date of death in RPDB is less than 4 months AFTER index date  
(rationale: same exclusion as kidney donors). 
9) Age<18 on index date 
10) Age >75 on index date 
11) Date of Last Contact (DOLC) is less than 4 months AFTER index date  
(rationale: same exclusion as kidney donors).  
12) Zero or > 4 physician visits in 2 years prior to index date (No matter how many 
physicians an individual sees on a given day, or the amount of codes that a physician bills for 
on a given day, this is still only counted as one visit. Physician visits defined by spec variable 
in the OHIP data – any spec that corresponds to a ‘physician’ (column C, physician “yes” in 
excel sheet attached). 
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specialty codes.xls
 
Exclude if any of the following (from July 1991, up to and including the index 
date): 
13) Diabetes (if date of onset of condition in ODD is before or equal to index date) 
14) Hypertension (if date of onset of condition in OHD is before or equal to index date) 
15) Cancer 
16) Cardiovascular disease 
17) Any prior cardiovascular procedure 
18) Pulmonary disease 
19) Liver disease 
20) Systemic lupus erythematosus 
21) Rheumatoid arthritis 
22) HIV 
23) Listed in TGLN as a kidney donor or recipient (control_ikn=don_ikn OR 
receipt_ikn from July 1991 to index date) 
24) Genitourinary disease  
25) Nephrectomy  
26) Any prior renal biopsy 
27) Exclude if ≥ 1 dialysis code from Appendix A (CIHI or OHIP code) from July 
1
st
, 1991 to 4 months after index date 
 
28) Exclude if have ever seen a nephrologist in consultation: 
    A consultation is identified by OHIP code A135, billed by a 
nephrologist on either an outpatient or inpatient visit, where a nephrologist 
is defined as a physician who had both a) and b) anytime during the study 
accrual window [window is July 1,1991 to March 31,2009]. 
a. billed an A135 code ≥50 times during the accrual period (can be same 
patient) 
b. billed renal dialysis code ≥50 times during accrual period [any OHIP 
fee code in Appendix A under category “Hemodialysis”, “Peritoneal 
Dialysis” or “Other”, but not “Continuous Renal Replacement 
Therapy”; note: can be same patient] 
 
 Ensures that controls are extremely healthy in regards to renal function, 
specifically. 
 
Exclude if any of the following: 
61 
 
29) Pregnant at the time of index date (defined by evidence of ≥ 1 birth code, in 2 
months prior to index date to 6 months after index date; birth codes presented in 
Appendix B) 
 
30) Gestational diabetes prior to index date  
31) Pre-eclampsia prior to index date  
       
32) Evidence of kidney stones with surgical intervention prior to the index date 
and 7 days after index date: 
 
    
33) Evidence of other hospital encounter for kidney stones prior to index date and 
7 days after index date 
     
 
Time frame definitions 
 
 
 
 
 
 
 
Index date 
Donors: Date of donation in TGLN (TX_DATE) 
Controls: Matched to donors (see “Matching Variables” section) 
Accrual window July 1, 1992 to March 31, 2009 
Look-back window Variable look-back window to July 1991 for all subjects to ascertain exclusion 
criteria 
Max follow-up March 31, 2012 for all subjects 
 
Observation Observation window terminates when the first of the following censoring 
Look-back Window 
 
Observation Window 
Index date 
Accrual Window Max Follow-up Date 
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window 
termination 
events occurs: 
1. March 31, 2012 (end of the study) 
2. Emigration: For patients who haven’t died prior to end of study (March 
31, 2012), if time between Date of Last Contact (DOLC, ICES variable) and 
end of study (March 31, 2012) is >3 years, censor at 1 year after DOLC 
3. Death 
 
Variable definitions 
 
Exposure 
 
Living kidney donation, defined by entry in TGLN as a donor. 
Baseline 
Characteristics 
(see Table 2a and 
2b) 
Observed at time of index date: 
Record mean, median, categorical number (%) for the following variables in Table 2a: 
 
1. Year of index date (report as calendar year) 
2. Age at index date 
3. Gender (Female, N (%)) 
4. Income quintile, for missing impute as 3 (median income) for purposes 
of matching  
5. Residency status, rural or urban (Report only categorical number, (%)); 
for ‘missing’, code this as urban 
 
Look back 1 year from index date:  
 
6. Health care use  
[Physicians and non-physicians should be defined using OHIP billing – spec 
data] 
 Non-physician health care professional visits (defined below; if multiple 
codes on a single day only count once (%). No difference is expected in the 
numbers for donors and controls.  
Physician visits (divided into categories, any spec that corresponds to a 
‘physician’ (column C, physician “yes” in previously attached excel sheet; if 
more than one physician visit on a single day only count once) by the number 
of visits) (%). Donors are expected to have more physician visits than 
controls. 
 
Code  Non-Physician Visits (definition for current study) 
49 DENTAL SURGERY (dentistry) 
50 ORAL SURGERY (dentistry) 
51 ORTHODONTICS (dentistry) 
53 PERIODONTICS (dentistry) 
54 ORAL PATHOLOGY (dentistry) 
55 ENDODONTICS (dentistry) 
56 OPTOMETRISTS 
58 CHIROPODISTS 
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59 CHIROPRACTOR 
70 ORAL RADIOLOGY (dentistry) 
71 PROSTHODONTICS (dentistry) 
80 PHYSIOTHERAPY (HOME) 
81 PHYSIOTHERAPY (HOME/OFFICE) 
 
Observed at end of follow-up: 
7. Age at last follow-up 
 
Donor characteristics only (Table 2b: These data come from TGLN 
database):  
 
8. Donor relationship to recipient (TGLN variable Relationship) 
9. Method of nephrectomy (TGLN variable D_SURG_TYPE) 
 
 
Matching 
Variables 
 
Match 10 non-donor controls to each donor based on the following five (5) 
variables, in order:  
1. Index date (±6 months) 
2. Gender 
3. Age (±2 years) 
4. Income quintile (same quintile; if ‘missing’, value is ‘3’) 
5. Residential status (same status, rural or urban; if ‘missing’, code as 
‘urban’)  
 
NB: If not possible to find 10 controls who meet all criteria, choose the 
maximum number of controls who do meet all the criteria. Report number of 
controls achieved in Table 3. 
 
Assign a unique “Group ID” value to each matched group (1 donor, 10 
controls) 
 
 
Primary outcome 
 
Evidence of kidney stone with surgical intervention following the index date 
until March 31, 2012 (see Appendix D for codes, use CIHI-DAD, CIHI-SDS, 
NACRS-ED). 
  
Note: Participants can have more than one occurrence of a kidney stone with 
surgical intervention during follow-up, but such interventions must be 
separated by at least 90 days to ensure it is for a new stone or reoccurrence 
of a stone. 
 
64 
 
 
Secondary 
outcomes 
 
1. Evidence of hospital encounter for kidney stones following the index 
date until March 31, 2012  (Appendix D and E together, use CIHI-DAD, CIHI-
SDS and NACRS-ED) 
 
            
 
2. Time to first kidney stone with surgical intervention following the 
index date until March 31, 2012  
 
              
 
3. Time to first hospital encounter for a kidney stone following the index 
date until March 31, 2012  
            
 
Outline of analysis plan 
 
Steps to Identify 
Controls Matched 
to Donors 
 
1. Restrict controls to individuals in the RPDB who have a valid IKN, 
date of birth, gender and meet first step of inclusion criteria. 
2. Randomly assign an index date (July 1, 1992 – March 31, 2009) to all 
eligible individuals in the RPDB. Assign these index dates to match the 
distribution in the LKD cohort (TGLN dataset) based on the minimum, 
maximum, 25
th
, 50
th
 and 75
th
 percentile of the index dates in the LKD cohort. 
NB: Match the index date distribution after applying inclusion and exclusion 
criteria to the LKD cohort. 
3. Apply exclusion criteria to individuals from the RPDB to determine 
eligible controls. 
4. Match 10 controls to each donor (see “Matching Variables” section). 
5. Each individual from the RPDB may serve as a control for no more 
than one donor. 
 
Record level of matching achieved in Table 3. 
 
 
Exploratory and 
 
- Apply exclusion criteria and identify number of donors and controls 
lost (see Tables 1a and 1b).  
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Descriptive 
Analyses 
- Provide the frequencies and descriptive characteristics for all baseline 
characteristics for both donors and controls (Table 2a and 2b). 
 Report standardized differences; to calculate standardized difference 
see below 
 
Statistics in Medicine 
(PS Matching diagnostics, 2009).pdf
 
 
 
Many-to-one 
matching diagnostics 2008.pdf
 
 
 
 
 Report % of missing data for each variable (should be no missing data), 
impute value of “3” for missing income (matching characteristic), impute 
‘urban’ value for missing urban/rural and discuss with team any other values 
with high level of missingness.  
- Report length of follow-up (max, min, mean, median and total person 
years) and distribution of censoring events (categorical number) in Table 4. 
As well report the number of persons who reached a maximal given year of 
follow-up (Table 5). 
- Report distribution of primary outcome events (categorical number) 
in Table 6. 
 
Primary analysis - Compare group differences using a negative binomial regression 
model to account for sources of statistical non-independence (multiple 
kidney stone events in a given individual, as well as the correlational 
structure within each matched set) 
- Report results in Table 7. 
 
Secondary analysis 
 
- Plot Kaplan-Meier (K-M) survival graphs for donors and controls 
(see Table 9a and 9b) 
 Compare group differences using two-sided log-rank test. This test 
needs to account for the ‘correlation’ within group_id (see Figure 1 below). In 
this analysis patients are censored for death, emigration and end of the follow-
up period (March 31, 2012). 
 To account for the correlation, the log rank test is stratified by the 
match (group_id). This means the log rank statistic is calculated within 
matched sets (group_id), and then is combined to get an overall statistic. It is 
NOT weighted by the number of matched controls per matched donor (the 
way Cox proportional hazard regression would be in this situation). 
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Figure 1. K-M survival curves for primary outcome time-to-first event (kidney stone with 
surgical intervention) analysis 
 
Patients censored for death, emigration and end of the follow-up period (March 31, 2012). 
Survival here refers to event free survival.  
 
Example (fictional data): 
 
 
Subgroup analyses 
 
Perform subgroup analyses for primary outcome only using interaction terms. 
Report results in Table 8. 
*Note: Organize the subgroup according to the donor characteristic with 
their associated matched controls, and report the associative measure and 
upper and lower confidence interval to 3 decimal points. We will then 
compute each interaction term separately with summary measures using the 
method of Bland and Altman.  
- Gender 
- Age, <40 vs. ≥40 at index date 
- Index date, from July 1992 to December 2001 vs. January 2002 to 
March 2009 
 
 Sets defined by the ‘donor characteristic’; non-donors in set follow 
donors.  
 Produce estimates of point estimate and 95% confidence interval for 
each stratum.  
 We will calculate test of interaction based on the output of point 
estimate, lower CI, and upper CI (Bland and Altman technique, embedded 
article below, double click icon to access). 
 
interaction altman 
and bland bmj article.pdf
  
 
Log-rank (LKDs vs. controls) 
(p = XXXX) 
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